In My Opinion; We Have Been Fed One Of The Most Dangerous Pharma Poisons To Come Down The Line
I am not anti-vaccine but it is high time that Americans wake up and get off their lazy, complacent asses and face the facts that so much of what we are fed by our government is corporate sponsored lies and damned near ventriloquist pronouncements from corporations who are selling the fear-laden, SHEEPLE of this nation who find it comfortable to accept any pronouncement without question, proof or full information.
In the case of the HPV vaccines we have been fed one of the most dangerous pharma poisons to come down the line. Pharmaceutical Companies publish long fold out lists of “possible” side effects with their prescription medications. How many of you have had one of those that when opened it was the size of a road map with a great of the information being totally unintelligible?
One does not get the chance to do that with a vaccine and as we have to know the CDC reporting system is less than complete or trust worthy. With the reported injuries and deaths associated with this vaccine that we know of; there have been repeated calls for further study, and for a transparency that Merck is not about to provide unless forced to do so!
PROMOTING VACCINES TO BENEFIT MANUFACTURERS
Then, of course, there’s the issue of polysorbate 80, which has become another vaccine additive that antivaccinationists hate because, polysorbate 80 combines with aluminum in a horrific fashion:
The most frightening trait of polysorbate 80 may be that it crosses the blood-brain barrier and can take other substances with it. It is used for that purpose. The drugs loperamide4 and doxorubicin5 are coated with polysorbate for just this purpose—to drag them into the brain.
So what else can polysorbate 80 drag into the brain? Gardasil utilizes aluminum as an adjuvant, even though it’s a dangerous neurotoxin. Injection of aluminum is associated with several neurological disorders, as is reported in Gaia Health and Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations6, rheumatoid arthritis, autoimmune thyroid disease, inflammatory bowel disease, multiple sclerosis, diabetes, and autism may all be associated with aluminum adjuvants in vaccines.
Can polysorbate open the blood-brain barrier to let aluminum in? No one really knows because no one has looked. There is, though, no legitimate reason to assume that it cannot.
This research was carried out to determine whether or not some serious autoimmune and neurological ADRs following HPV vaccination are causal or merely coincidental and to validate a biomarker-based immunohistochemical (IHC) protocol for assessing causality in case of vaccination-suspected serious adverse neurological outcomes.
Methods: Post-mortem brain tissue specimens from two young women who suffered from cerebral vasculitis- type symptoms following vaccination with the HPV vaccine Gardasil were analysed by IHC for various immuno- inflammatory markers. Brain sections were also stained for antibodies recognizing HPV-16L1 and HPV-18L1 antigen which are present in Gardasil.
Results: In both cases, the autopsy revealed no anatomical, microbiological nor toxicological findings that might have explained the death of the individuals. In contrast, our IHC analysis showed evidence of an autoimmune vasculitis potentially triggered by the cross-reactive HPV-16L1 antibodies binding to the wall of cerebral blood vessels in all examined brain samples. We also detected the presence of HPV-16L1 particles within the cerebral vasculature with some HPV-16L1 particles adhering to the blood vessel walls. HPV-18L1 antibodies did not bind to cerebral blood vessels nor any other neural tissues. IHC also showed increased T-cell signalling and marked activation of the classical antibody-dependent complement pathway in cerebral vascular tissues from both cases.
This pattern of complement activation in the absence of an active brain infection indicates an abnormal triggering of the immune response in which the immune attack is directed towards self-tissue.
Conclusions: Our study suggests that HPV vaccines containing HPV-16L1 antigens pose an inherent risk for triggering potentially fatal autoimmune vasculopathies.
Practice implications: Cerebral vasculitis is a serious disease which typically results in fatal outcomes when undiagnosed and left untreated. The fact that many of the symptoms reported to vaccine safety surveillance databases following HPV vaccination are indicative of cerebral vasculitis, but are unrecognized as such (i.e., intense persistent migraines, syncope, seizures, tremors and tingling, myalgia, locomotor abnormalities, psychotic symptoms and cognitive deficits), is a serious concern in light of the present findings. It thus appears that in some cases vaccination may be the triggering factor of fatal autoimmune/neurological events. Physicians should be aware of this association.
Judicial Watch announced it has received documents from the Department of Health and Human Services (HHS) revealing that its National Vaccine Injury Compensation Program (VICP) has awarded $5,877,710 dollars to 49 victims in claims made against the highly controversial HPV (human papillomavirus) vaccines. To date 200 claims have been filed with VICP, with barely half adjudicated.
“This new information from the government shows that the serious safety concerns about the use of Gardasil have been well-founded. Public health officials should stop pushing Gardasil on children.” said Judicial Watch President Tom Fitton.
The CDC recommends the Gardasil vaccine, made by Merck Pharmaceuticals, for all females between 9 and 26 years to protect against HPV. Furthermore, the CDC says Gardasil is licensed, safe, and effective for males ages 9 through 26 years.
The facts appear to contradict the FDA’s safety statements. The adverse reaction reports detail 26 new deaths reported between September 1, 2010 and September 15, 2011 as well as incidents of seizures, paralysis, blindness, pancreatitis, speech problems, short term memory loss and Guillain-Barré Syndrome. The documents come from the FDA’s Vaccine Adverse Event Reporting System (VAERS) which is used by the FDA to monitor the safety of vaccines.
That’s 26 reported deaths of young, previously healthy, girls after Gardasil vaccination in just one year.
In response to the concern about death reports among those who received Gardasil, the Centers for Disease Control (CDC) insists “there was no unusual pattern or clustering to the deaths that would suggest that they were caused by the vaccine.”
While it is not clear exactly what is causing so many adverse reactions, Gardasil does contain genetically engineered virus-like protein particles as well as aluminum, which can affect immune function.
Further, according to the vaccine manufacturer product information insert, “Gardasil … not been evaluated for carcinogenicity or impairment of fertility.” (2007  p1986 )
In fact, Merck studied the Gardasil vaccine in fewer than 1,200 girls under 16 prior to it being released to the market under a fast-tracked road to licensure. To date, most of the serious side effects, including deaths, that occurred during the pre-licensure clinical trials and post marketing surveillance have been written off as a “coincidence” by Merck researchers and government health officials.
Neurologist Dr. Ian Sutton reported negative neurological side effects from Gardasil. He reported five cases of multiple sclerosis-like symptoms emerging shortly after women received the Gardasil vaccine, noting:
“We report five patients who presented with multifocal or atypical demyelinating syndromes within 21 days of immunization with the quadrivalent human papilloma virus (HPV) vaccine, Gardasil. Although the target population for vaccination, young females, has an inherently high risk for MS, the temporal association with demyelinating events in these cases may be explained by the potent immuno-stimulatory properties of HPV virus-like particles which comprise the vaccine.”
From its inception, the use of HPV (human papillomavirus) vaccines for sexually transmitted diseases has been hotly disputed. According to the Annals of Medicine: “At present there are no significant data showing that either Gardasil or Cervarix (GlaxoSmithKline) can prevent any type of cervical cancer since the testing period employed was too short to evaluate long-term benefits of HPV vaccination.”
There are more than 100 types of human papillomaviruses (HPVs). Of them, about 40 types of HPV are sexually transmitted and 15 of these types are most associated with cervical cancers and genital warts in women and men.
HPV vaccines have been illegally administered to millions without informed consent, as the risks rarely disclosed.
Not only are there questions about the safety of the vaccine, there are questions about the need for the vaccine. Over 90 percent of women infected with HPV clear the infection naturally within two years, at which point cervical cells go back to normal.
Meanwhile, Merck is benefitting tremendously from vaccine sales. The vaccine is expected to reach $1 billion in sales next year, and could reach more than $4 billion in sales in five years, according to Wall Street analysts.
Read more: http://communities.washingtontimes.com/neighborhood/stress-and-health-dr-lind/2013/apr/10/us-court-pays-6-million-gardasil-victims/#ixzz2uRKsAdgL
Follow us: @wtcommunities on Twitter
February 10, 2014 | By Arlene Weintraub
The President's Cancer Panel is urging federal and state health authorities to do a better job protecting children from preventable cancers by improving access to the HPV vaccine--and if the group's suggestions are taken seriously, it could mean a big bump in sales of the two HPV vaccines on the market, GlaxoSmithKline's ($GSK) Cervarix and Merck's ($MRK) Gardasil.
Only about a third of teenage girls have been vaccinated and less than 7% of boys received the vaccine in 2012, according to the President's Cancer Panel report. (Gardasil was approved for use in males in 2009.)
"We are confident that if HPV vaccination for girls and boys is made a public health priority, hundreds of thousands will be protected from these HPV-associated diseases and cancers over their lifetimes," said Barbara K. Rimer, chair of the President's Cancer Panel, in a press release. Specifically, the Centers for Disease Control estimates that increasing HPV vaccination rates to 80% would prevent 53,000 future diagnoses of cervical cancer, the report says.
The President's Cancer Panel has laid out several recommendations for making the HPV vaccines more popular, including marketing them more effectively to physicians, allowing more pharmacists to administer the vaccine, and launching communications campaigns aimed at increasing acceptance among parents.
That last one could be challenging. In addition to broad concerns about vaccines being unsafe, there's a widespread perception among parents that vaccinating children against HPV encourages promiscuity, even though a growing body of evidence suggests that's not the case. For example, in a recent edition of the journal Pediatrics, researchers funded by the National Institutes of Health reported that most young women who receive the HPV vaccine understand they must practice safe sex, and most do not become more promiscuous after vaccination.
The panel recommends using social media, print and electronic communications strategies to change parents' attitudes about HPV vaccination. "The conversation needs to be framed around cancer prevention, not about sex," Rimer told USA Today.
The recommendations could mean a reversal of fortune for Gardasil and Cervarix, both of which have seen a slowdown in sales growth in the wake of concerns over safety and sex. Sales of Gardasil grew 12% year-over-year to $1.8 billion in 2013, falling far short of the 35% sales growth the product achieved in 2012. Sales of Cervarix fell 37% last year to 172 million British pounds ($282 million).
- here's the press release from the President's Cancer Panel
- check out the President's Cancer Panel's full report
- read more at USA Today
WASHINGTON, Feb. 10, 2014 /PRNewswire-USNewswire/ -- Achieving widespread HPV (human papillomavirus) vaccination is one of the most profound opportunities for cancer prevention, according to a report released today by the President's Cancer Panel. The Panel's report, Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer, issues an urgent call for energizing efforts to reach the HPV vaccines' potential to save lives and prevent millions of avoidable cancers and HPV-related conditions in men and women. One in four people in the U.S. are infected with at least one type of HPV, a group of viruses linked to multiple cancers and other diseases. The report examines underuse of HPV vaccines, identifies key barriers to increasing vaccine uptake, and provides actionable recommendations for overcoming these obstacles.
"Today, there are two safe, effective, approved vaccines that prevent infection by the two most prevalent cancer-causing types, yet vaccination rates are far too low," said Barbara K. Rimer, DrPH, chair of the President's Cancer Panel. "We are confident that if HPV vaccination for girls and boys is made a public health priority, hundreds of thousands will be protected from these HPV-associated diseases and cancers over their lifetimes."
According to the report, based on data from the Centers for Disease Control and Prevention, in 2012 only about one-third of 13- to 17-year-old girls in the U.S. received all three recommended doses of HPV vaccine. These rates fall considerably short of the U.S. Department of Health and Human Services Healthy People 2020 goal of having 80 percent of 13- to 15-year-old girls fully vaccinated against HPV. Immunization rates for boys are even lower – less than 7 percent of boys ages 13-17 completed the vaccine series in 2012 (although the vaccine was approved for males more recently than for females).
The CDC estimates that increasing HPV vaccination rates from current levels to 80 percent would prevent an additional 53,000 future cervical cancer cases in the U.S. among girls who now are 12 years of age or younger, over the course of their lifetimes. Thousands of cases of other HPV-associated cancers in the U.S., a growing proportion of which will occur in males, also likely would be prevented within the same timeframe.
The Panel's report outlines three critical goals that must be achieved to increase HPV vaccine uptake – Reducing missed clinical opportunities to recommend/administer HPV vaccines; Increasing parents'/adolescents' acceptance of HPV vaccines; and Maximizing access to HPV vaccination services – with the ultimate goal being completion of the full three-dose series by all age-eligible adolescents.
Key Findings and Recommendations:
According to the CDC, missed clinical opportunities are the most important reason why the U.S. has not achieved high rates of HPV vaccine uptake. As many as two-thirds of 11- and 12-year-old vaccine-eligible girls may not be receiving HPV vaccines at healthcare visits during which they receive at least one other vaccine. The Panel recommends targeted efforts, including communications strategies for physicians and other relevant health professionals, to increase dramatically the proportion of health providers who strongly recommend HPV vaccines for age-eligible adolescents. Use of EHRs (electronic health records) and immunization information systems can help to avoid missed opportunities for HPV vaccination and facilitate completion of the three dose regimen.
Parents' and other caregivers' knowledge, attitudes, and beliefs affect whether children receive vaccines, including HPV vaccines. Studies have provided insights into parents' views, including that some parents of young adolescents may believe they can wait to vaccinate their children against HPV. To increase HPV vaccine acceptance among parents, caregivers, and adolescents, the Panel recommends targeted efforts, including the deployment of integrated, comprehensive communications strategies, using social media, print, electronic communications and the persuasive authority of health care providers interacting with empowered patients.
Vaccines should be available where adolescents receive healthcare. It should be convenient to initiate and complete the HPV vaccine series, and cost should not be a barrier. The Panel recommends increasing the range of venues and providers for HPV vaccination, including venues outside the medical home, such as pharmacies. A 2012 survey of representatives of state pharmacy organizations in all 50 states and the District of Columbia found that pharmacists in more than one-third of states were not permitted to administer HPV vaccines to 12-year-old girls, though many of these states allowed pharmacists to provide HPV vaccines to women ages 19 and older.
Additionally, the burden of HPV-associated cancers extends beyond the borders of the United States, affecting populations in every country. The Panel calls for continued investment in and implementation of HPV vaccination programs in low-and middle-income countries, where the majority of HPV-associated cancer cases occur.
Starting on February 10, 2014, the complete report can be accessed at http://deainfo.nci.nih.gov/advisory/pcp/annualReports/HPV/index.htm. Hard copies may be requested by writing to firstname.lastname@example.org or President's Cancer Panel, 9000 Rockville Pike, Building 31, Room B2B37, MSC 2590, Bethesda, MD 20892.
The President's Cancer Panel consists of three members appointed by the President of the United States. Current members are Barbara Rimer, DrPH, Chair, Dean and Alumni Distinguished Professor, UNC Gillings School of Global Public Health; Hill Harper, JD, cancer survivor, four-time New York Times Best-Selling Author, actor, and philanthropist; and Owen Witte, MD, Director, UCLA Eli and Edythe Broad Center of Regenerative Medicine, and Stem Cell Research Investigator, Howard Hughes Medical Institute.
The Panel, established by the National Cancer Act of 1971, is an independent entity charged with monitoring the National Cancer Program and reporting annually to the President on any barriers to its execution.
The Panel does not conduct scientific research, and while support for the Panel is provided by the National Cancer Institute (NCI) at the National Institutes of Health under the Department of Health and Human Services, its conclusions and recommendations should not be inferred as policy or perspectives of the NCI.
More information about the Panel's role and background on its members can be found at pcp.cancer.gov.
SOURCE President's Cancer Panel
· President's Cancer Panel
9000 Rockville Pike
Building 31, Room B2B37, MSC 2590
Bethesda, MD 20892
President's Cancer Panel Direct Number: 301-451-9399
· E-mail PCP at: email@example.com
A new review published in Autoimmunity Reviews titled, "On the relationship between human papilloma virus vaccine and autoimmune disease," is destined to reopen the controversy surrounding numerous reports of HPV vaccine-induced harm that have surfaced ever since their widespread use, beginning with the FDA's 2006 approval of Merck & Co.'s Gardasil.[i]
The study points out, "Along with the introduction of the HPV vaccines, several cases of onset or exacerbations of autoimmune diseases following the vaccine shot have been reported in the literature and pharmacovigilance databases, triggering concerns about its safety."
Following an extensive review of the biomedical literature, they listed conditions in which HPV vaccination is most likely linked to the development of autoimmune diseases (with qualification that they are only raising possible links and not fully confirmed ones), including:
· Acute disseminated encephalomyelitis and other demyelinating diseases of the central nervous system
· Multiple sclerosis (MS)
· Guillain–Barré syndrome (GBS)
· Primary ovarian failure (POF)
· IgA bullosus dermatitis
· Henoch-Schonlein purpura
· Cutaneous vasculitis
· Kikuch-Fujimoto disease
· Erythema multiforme
· Acute cerebral ataxia
· Immune thrombocytopenic purpura
The authors caution that, "The decision to vaccinate with HPV vaccine is a personal decision, not one that must be made for public health. HPV is not a lethal disease in 95% of the infections; and the other 5% are detectable and treatable in the precancerous stage."
HPV Vaccines May Cause The Immune System To Attack Body
How could a vaccine that has been declared safe and effective the world over be connected to such a wide range of autoimmune diseases?
Part of the explanation lies with a phenomena known as 'molecular mimicry,' defined as the possibility that the immune system will mistake a self-structure with a foreign (usually pathogen derived) peptide and thereby cause auto-immune harm. Antibodies, for instance, which are produced against a specific pathogen can cross-react with proteins in the body that have a similar or identical sequence.
Exactly this possibility is addressed in a groundbreaking article titled, "Quantifying the possible cross-reactivity risk of an HPV16 vaccine," published in 2009 in the Journal of Experimental Therapeutics and Oncology. The article describes the background for the topic as follows:
"The potential adverse events associated with vaccination for infectious diseases underscore the need for effective analysis and definition of possible vaccine side effects. Using the HPV16 proteome as a model, we quantified the actual and theoretical risks of anti-HPV16 vaccination, and defined the potential disease spectrum derived from concomitant cross-reactions with the human organism."
The HPV16 proteome is the entire spectrum of proteins produced by the HPV16 virus, which are present within both the Gardasil and Cervarix HPV vaccines. Each protein carries a risk of inducing an immune response that could, in theory, 'blow back' on self-structures within the human proteome. With this possibility in mind, the researchers used the following method to ascertain the likelihood of such an event:
"We searched the primary sequence of the HPV16 proteome for heptamer amino acid sequences shared with human proteins using the Protein International Resource database."
Heptamer amino acid sequences are defined as an oligomers (molecular complex) with seven subunits.
The results of their search revealed a profound degree of matching:
"The human proteome contains 82 heptapeptides and two octapeptides found in HPV16. The viral matches are spread among proteins involved in fundamental processes, such as cell differentiation and growth and neurosensory regulation. The human proteins containing the HPV16-derived heptamers include cell-adhesion molecules, leukocyte differentiation antigens, enzymes, proteins associated with spermatogenesis, transcription factors, and neuronal antigens. The number of viral matches and their locations make the occurrence of side autoimmune cross-reactions in the human host following HPV16-based vaccination almost unavoidable." [emphasis added]
The so-called "unavoidability" of "side autoimmune cross reactions in the human host following HPV16-based vaccination" is a huge concern, especially considering that there are 4 strains in total in the Gardasil vaccine and 2 in the Cervarix, increasing the range of proteomic overlap between viral and human proteins and subsequent molecular mimicry significantly. Also, it is important to acknowledge that the vaccine has never even been found to prevent one single case of death from cervical cancer, and yet millions are being exposed to what are likely its unavoidable health risks.
HPV Vaccines Don't Work As Advertised and Lack Safety
In an article published in 2013 in the journal Infectious Agent Cancer, titled "HPV vaccines and cancer prevention, science versus activism," the rationale behind current worldwide HPV vaccination programs is called into question.
The basic premise of global immunization campaigns are described as follows:
"1) that HPV vaccines will prevent cervical cancers and save lives and, 2) have no risk of serious side effects. Therefore, efforts should be made to get as many pre-adolescent girls vaccinated in order to decrease the burden of cervical cancer."
Despite this, the authors claim, "Careful analysis of HPV vaccine pre- and post-licensure data shows however that both of these premises are at odds with factual evidence and are largely derived from significant misinterpretation of available data."
The authors explain:
"In spite of much unwarranted and premature optimism, the fact is however that HPV vaccines have not thus far prevented a single case of cervical cancer (let alone cervical cancer death). Instead, what the clinical trials have shown is that HPV vaccines can prevent some of the pre-cancerous CIN 2/3 lesions associated with HPV-16 and HPV-18 infection, a large fraction of which would spontaneously resolve regardless of the vaccination status [2-4]. For example, in adolescent women aged 13 to 24 years, 38% of CIN 2 resolve after one year, 63% after two and 68% after three years . Moreover, the validity of CIN 2 being a cancer precursor is questionable due to high misclassification rates and poor intra- and inter-observer reproducibility in diagnosis, as well as high regression rates [6-9]. According to Castle et al.  CIN 2 is the least reproducible of all histopathologic diagnoses and may in part reflect sampling error. While CIN 3 is a more reliable marker for cancer progression than CIN 2, the use of this marker is not without caveats [2,10]."
Moreover, the presumed safety of HPV vaccines is not supported by the facts:
Similarly, the notion that HPV vaccines have an impressive safety profile can only be supported by highly flawed design of safety trials [2,13] and is contrary to accumulating evidence from vaccine safety surveillance databases and case reports which continue to link HPV vaccination to serious adverse outcomes (including death and permanent disabilities) [2,4,14]. For example, compared to all other vaccines in the U.S. vaccination schedule, Gardasil alone is associated with 61% of all serious adverse reactions (including 63.8% of all deaths and 81.2% cases of permanent disability) in females younger than 30 years of age .
Although a report to a vaccine safety surveillance system does not by itself prove that the vaccine caused an adverse reaction, the unusually high frequency of adverse reactions related to HPV vaccines reported worldwide, as well as their consistent pattern (i.e. nervous system-related disorders rank the highest in frequency), points to a potentially causal relationship . Furthermore, matching the data from vaccine surveillance databases is an increasing number of case reports documenting similar serious adverse reactions associated with HPV vaccine administration, with nervous system and autoimmune disorders being the most frequently reported in the medical literature [15-24].
The article summarizes their findings as follows:
"In summary, the optimistic claims that HPV vaccines will prevent cervical cancers and save lives, and that they are extremely safe, rest on assumptions which are misinterpreted and presented to the public as factual evidence. We thus conclude that further reduction of cervical cancers might be best achieved by optimizing cervical screening (which carries no serious health risks) and targeting other factors of the disease rather than by the reliance on vaccines with questionable efficacy and safety profiles [2,25]."
Considering also the recent discovery that HPV vaccines aren't effective at protecting African-American women, policy-makers need to reformulate their message for a wide range of reasons. The fact that the vaccines aren't nearly as effective as advertised, and clearly lack industry independent assurance of their safety, brings to the question the issue of informed consent. If the public is not being provided with the information required to make an informed choice, and immunization policy is based upon cultivating faith in a higher authority and not the evidence itself, clearly, the time has come for people to take back control of their own health, beginning perhaps with exploring the primary literature on the topic themselves in greater depth.
For additional research on HPV vaccine linked adverse effects, use our database section on the topic:HPV Vaccine Adverse Effects.
Sayer Ji is the founder of GreenMedInfo.com, an author, researcher, lecturer, and an advisory board member of the National Health Federation. Google Plus Profile. His writings have been published and referenced widely in print and online, including, Truthout, Mercola.com, New York Times online, The Journal of Gluten Sensitivity, New York Times and The Well Being Journal.
He founded Greenmedinfo.com in 2008 in order to provide the world an open access, evidence-based resource supporting natural and integrative modalities. It is widely recognized as the most widely referenced health resource of its kind.